RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
received:
18
01
2022
accepted:
06
05
2022
pubmed:
17
8
2022
medline:
8
11
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
Noninvasive criteria to predict the progression of low-risk esophageal varices (EV) in patients with compensated hepatitis C virus (HCV) cirrhosis after sustained virological response (SVR) by direct-acting antivirals (DAAs) are lacking. Our aim was to assess the diagnostic performance of Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) criteria for EV progression compared with elastography-based criteria (Baveno VI, Expanded Baveno VI, and Baveno VII-HCV criteria). All consecutive patients observed at 3 referral centers with compensated HCV cirrhosis with or without F1 EV who achieved sustained virological response by DAAs were classified at last esophagogastroduodenoscopy (EGDS) as RESIST-HCV low risk (i.e., low probability of high-risk varices [HRV]) if platelets were >120 × 10 9 /L and serum albumin >3.6 g/dL or RESIST-HCV high risk (i.e., high probability of HRV) if platelets were <120 × 10 9 /L or serum albumin <3.6 g/dL. The primary outcome was the progression to HRV. The area under the receiver operating characteristic curve and decision curve analysis of noninvasive criteria were calculated. The cohort consisted of 353 patients in Child-Pugh class A (mean age 67.2 years, 53.8% males). During a mean follow-up of 44.2 months, 34 patients (9.6%, 95% CI 6.7%-13.5%) developed HRV. At the last EGDS, 178 patients (50.4%) were RESIST-low risk, and 175 (49.6%) were RESIST-high risk. RESIST-HCV criteria showed the highest area under the receiver operating characteristic curve (0.70, 95% confidence interval 0.65-0.75), correctly sparing the highest number of EGDS (54.3%), with the lowest false-positive rate (45.7%), compared with elastography-based criteria. Decision curve analysis showed that RESIST-HCV had higher clinical utility than elastography-based criteria. Biochemical-based RESIST-HCV criteria are useful to easily predict HRV development after HCV eradication by DAAs in patients with compensated cirrhosis and low-risk EV.
Identifiants
pubmed: 35973181
doi: 10.14309/ajg.0000000000001878
pii: 00000434-202211000-00023
doi:
Substances chimiques
Antiviral Agents
0
Serum Albumin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1816-1824Informations de copyright
Copyright © 2022 by The American College of Gastroenterology.
Références
D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44(1):217–31.
D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol 2018;68:563–76.
de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–52.
Augustin S, Pons M, Maurice JB, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 2017;66:1980–8.
Maurice JB, Brodkin E, Arnold F, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol 2016;65:899–905.
Augustin S, Pons M, Genesca J. Validating the Baveno VI recommendations for screening varices. J Hepatol 2017;66:459–60.
Cardenas A, Mendez-Bocanegra A. Report of the Baveno VI Consensus Workshop. Ann Hepatol 2016;15:289–90.
Thabut D, Bureau C, Layese R, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 2019;156:997–e5.
Petta S, Sebastiani G, Bugianesi E, et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. J Hepatol 2018;69:878–85.
Calvaruso V, Cacciola I, Licata A, et al. Is transient elastography needed for noninvasive assessment of high-risk varices? The REAL experience. Am J Gastroenterol 2019;114:1275–82.
SharmaAgarwal SS, Gunjan D, Kaushal K, et al. Deciding among noninvasive tools for predicting varices needing treatment in chronic liver disease: An analysis of Asian cohort. Am J Gastroenterol 2020;115:1650–6.
Duan Z, Li L, Li J, et al. Validation of the combined model based on platelet count and albumin to rule out high-risk varices in liver cirrhosis. Biomed Res Int 2020;2020:5783748.
Spearman CW, Dusheiko GM, Hellard M, et al. Hepatitis C. Lancet 2019;394:1451–66.
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol 2022;76:959–74.
Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411–e4.
North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: A prospective multicenter study. N Engl J Med 1988;319:983–9.
Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 2006;26:565–74.
Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res 2019;3:18.
Zhang Z, Rousson V, Lee WC, et al. Decision curve analysis: A technical note. Ann Transl Med 2018;6:308.
Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692–9.
Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017;153:1273–e1.
Mendizabal M, Piñero F, Ridruejo E, et al. Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2020;18:2554–e3.
Calvaruso V, Petta S, Cacciola I, et al. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. J Hepatol 2018;68:S83.
Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol 2020;73:1548–56.
D'Ambrosio R, Degasperi E, Anolli MP, et al. Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022;76(2):302–10.
Aghemo A, Masarone M, Montagnese S, et al.; Associazione Italiana Studio Fegato (AISF). Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the liver. Dig Liver Dis 2020;52:937–41.
2020 GI Endoscopy Coding And Reimbursement Guide. ( https://www.cookmedical.com/wp-content/uploads/2019/12/RG_ESC_50099_RE_202001.pdf ). Accessed December 15, 2021